Author

admin

Browsing

Nuvau Minerals Inc. (TSXV: NMC) has begun its minimum 1,500 m drill program aimed at testing continuity and extensions to the orogenic gold system discovered last month. The discovery was made with the first hole drilled of an inaugural gold-focused exploration program, in the footwall of the Bracemac-McLeod Mine approximately 200 m below surface. The follow-up program is being drilled immediately north east of this base metal mine, which was in production until mid 2022.

The Matagami Property is in the northern Abitibi Region of Quebec, one of the world’s most prolific gold endowed districts. This northern part of the Abitibi region includes Canada’s largest gold producing mine with the country’s largest gold mineral reserves: the Detour Lake Mine owned by Agnico Eagle Mines Limited. Hecla Mining Company’s Casa Berardi Mine, which has produced over 3 million ounces of gold, is located to the southwest of the Matagami Property (see Figure 1 below).

While the Abitibi’s first recorded gold discovery was 119 years ago in Rouyn-Noranda, the Matagami Property remains one of the largest areas in the region that has not been subject to a gold focused exploration program. Previous owners were concentrating on defining and developing multiple VMS deposits into multiple mines that produced extensive copper and zinc for more than 60 years. This was one of the primary opportunities Nuvau identified when it entered into the agreement to acquire the Property from Glencore. The Company recently began compiling gold related historic data, as well as launching several gold-focused initiatives (including till sampling) aimed at defining initial targets for drilling.

Figure 1: Matagami property location

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11236/262123_8f984e3ef4857b89_001full.jpg

Nuvau’s current gold-focused exploration program has identified three initial priority targets:

  1. Bracemac Footwall Discovery
  2. Gold-in-Till Anomaly Target
  3. Thunder Mine (1988) Target

The map below shows the location of these three targets (Figure 2). The vast majority of this 1,300 km2 land pack remains open for gold exploration.

Figure 2: Current gold targets

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11236/262123_8f984e3ef4857b89_002full.jpg

1. Bracemac Footwall Discovery

The recent discovery of gold mineralization in the footwall of the Bracemac Mine is located only 25 m from the access ramp of this permitted mine. The steeply dipping, strong shear zone structure with quartz veining mineralized with pyrite and locally visible gold was intersected at a depth of approximately 200 m. The visible gold was observed over approximately 0.5 m of core and assays are still pending on the discovery hole, BRCG-25-001.

Although located within the immediate footwall of the past-producing Bracemac-McLeod mine, the mineralized structure occurs in a late intrusive that truncated the mine host rock units (see Figure 3). The intrusive has seen very little drilling as the stratigraphy was not of interest for VMS exploration.

The follow up drill program is now underway to continue to step-out both up and down dip, and along strike, to test continuity of mineralization within the structural corridor as well as providing critical data on the dip and strike of the vein.

Figure 3: Past producing Bracemac-McLeod Mine and relative position of gold target drilled (left); schematic of the stratigraphy (right)

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11236/262123_figure3.jpg

Figure 4: Visible gold found in more than 30 gold chips identified in logging the core

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11236/262123_8f984e3ef4857b89_005full.jpg

2. Gold-in-Till Anomaly Target

As part of Nuvau’s target generative exploration program, an overburden (till) drilling program was launched in 2023. This program resulted in the discovery of significant gold-in-till mineralization that was announced on March 4, 2025.

From the 2023 sonic drill program, hole PD-23-030s produced a notable gold grain anomaly detected at a depth of between 29.26 to 29.87 m in the overburden and featured more than 2,000 gold grains per 10 kg of material. In addition, a near-contiguous sample with 295 gold grains per 10 kg of material between 31.12 to 32.00 m was also encountered with the interval between consisting of a large locally derived boulder. Based on the almost pristine nature of the gold grains, and their close proximity to the bottom of the hole, the source is expected to be relatively close to this hole. (See images of gold grains below in Figure 5.)

To assist in defining targets in this area, a detailed drone MAG survey was completed. The limited rock outcrops were also mapped recently and together with the MAG data, a drill program is being designed for later this year. The objective of this drill program will be to gain a better understanding of the local geological structures and to test for the potential source of the extensive gold grains.

Figure 5: Mosaic of backscattered electron images of gold grain

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11236/262123_figure5.jpg

Notice the delicate textures and silicate attachments. LEFT: Image of 230 gold grains found in sample 155320186, hole PD-23-030s, RIGHT: Image of 112 gold grains found in adjacent sample 155320187.

3. Thunder Mine (1988) Target

The Thunder Mine property was acquired by Nuvau in 2023 for its potential for both base metal and gold mineralization. In 1988, Thunderwood Exploration Ltd. drilled a series of holes as follow-up to a 1959 hole that intersected copper mineralization (see Figure 6).

This follow-up program identified multiple gold-bearing structures; however, no subsequent follow-up work was completed. Highlight intercepts from the available public domain report include the following:

  • DT-14-88: 209.00 – 209.80 m (0.80 m) @ 26.40 g/t Au.
  • DT-10-88: 205.00 – 206.00 m (1.00 m) @ 78.16 g/t Au.
  • DT-18-88: 100.80 – 107.30 m (6.50 m) @ 1.55 g/t Au, incl.: 0.30 m @ 4.89 g/t Au.
  • DT-19-88: 226.00 – 231.00 m (5.0 m) @ 2.27 g/t Au, Incl.: 0.50 m @ 10.39 g/t Au.
  • DT-20-88: 136.80 – 137.10 m (0.30 m) @ 10.37 g/t Au and 204.50 – 205.00 m (0.50 m) @ 6.48 g/t Au.
  • DT-21-88: 310.50 – 319.90 m (9.40 m) @ 4.02 g/t Au, incl.: 0.70 m @ 42.03 g/t Au and 0.70 m @ 7.30 g/t Au.

These results been extracted from historical information, and are not compliant with NI 43-101. The original results are available via GESTIM, GM 48216, and GM 08790 at the following links:

    Thunder mine drilling is planned as part of Nuvau’s winter drilling program in Q1 2026.

    Figure 6: Thunder Mine Past drilling

    To view an enhanced version of this graphic, please visit:
    https://images.newsfilecorp.com/files/11236/262123_8f984e3ef4857b89_012full.jpg

    About Nuvau Minerals Inc.
    Nuvau is a Canadian mining company focused on the Abitibi Region of mine-friendly Québec. Nuvau’s principal asset is the Matagami Property that is host to significant existing processing infrastructure and multiple mineral deposits and is being acquired from Glencore.

    Qualified Person and Quality Assurance
    Bastien Fresia P. Geo. (Qc), Technical Services Director of Nuvau and a ‘qualified person’ as is defined by National Instrument 43-101, has verified the scientific and technical data disclosed in this news release, and has otherwise reviewed and approved the scientific and technical information in this news release.

    Drill core samples are sawn by staff technicians to create half core splits. One split is retained in the drill core box for archival purposes with a sample tag affixed at each sample interval and the other split is placed in a labelled plastic bag along with a corresponding sample number tag and placed in the shipment queue.

    Quality control samples including blind certified reference material (‘CRM’), blank material, and core duplicates are inserted at a frequency of 1 in every 20 samples and sample batches of up to 60 samples were then shipped directly by Nuvau personnel to the ALS Canada Ltd. preparation laboratory in Rouyn-Noranda, Québec.

    All submitted core samples are crushed in full to 95 % passing less than 2 mm (ALS code CRU-32). A 1000-gram sample was then riffled split from the crushed material and pulverized to 90 % passing 75 μm (SPL-22 and PUL-32a). Pulps are shipped from the preparation laboratory to ALS Canada Ltd.’s analytical lab in North Vancouver, British Columbia, for assay.

    Lead, silver, copper and zinc analyses were determined by ore grade four acid digestion with an inductively coupled plasma atomic emission spectroscopy (‘ICP-AES’) or atomic absorption spectroscopy (‘AAS’) finish (ALS codes Pb-OG62, Ag-OG62, Cu-OG62 and ZnOG62), whereas gold was determined by 50 g fire assay analysis with an AAS finish (code Au-AA23).

    ALS Canada Ltd. is an accredited, independent commercial analytical firm registered to ISO/IEC 17025:2017 and ISO 9001:2015.

    For further information please contact:
    Nuvau Minerals Inc.
    Peter van Alphen
    President and CEO
    Telephone: 416-525-6023
    Email: pvanalphen@nuvauminerals.com

    Cautionary Statements
    This news release contains forward-looking statements and forward-looking information (collectively, ‘forward-looking statements’) within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as ‘may’, ‘should’, ‘anticipate’, ‘will’, ‘estimates’, ‘believes’, ‘intends’ ‘expects’ and similar expressions which are intended to identify forward-looking statements. More particularly and without limitation, this news release contains forward-looking statements concerning drill results relating to the Matagami Property, the results of the PEA, the potential of the Matagami Property, the timing and commencement of any production, the restart of the Bracemac-McLeod Mine, the completion of the earn-in of the Matagami Property and the timing and completion of any technical studies, feasibility studies or economic analyses. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company, including expectations and assumptions concerning the Company and the Matagami Property. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by the management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

    The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by securities law, neither the Company nor Nuvau undertakes any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262123

    News Provided by Newsfile via QuoteMedia

    This post appeared first on investingnews.com

    International Lithium Corp. (TSXV: ILC,OTC:ILHMF) (OTCQB: ILHMF) (FSE: IAH) (the ‘Company’ or ‘ILC’) is pleased to announce a non-brokered private placement (the ‘Offering’) of up to 66,666,667 common shares at CAD $0.015 per share to raise gross proceeds of up to $1,000,000. The Company may pay finders fees on a portion of the placement.

    Proceeds of the private placement will be used partly to allow the Company to invest in growing its Southern African and Canadian operations and partly for general working capital purposes. Payments to persons conducting Investor Relations activities are expected not to exceed 10% of the proceeds.

    Closing of the Offering is subject to acceptance by the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the date of issuance under applicable Canadian securities laws.

    It is anticipated that some directors and insiders will participate in this Offering. The issue of shares (to the extent subscribed for by insiders) constitute ‘related party transactions’ pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (‘MI 61-101’), as the subscribers include directors of the Company. The Company is exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the shares in reliance on the exemptions contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the fair market value of the shares does not exceed 25% of the Company’s market capitalization.

    The Company has now closed its non-brokered private placement originally announced on February 5, 2025. Under the terms of the private placement, the Company on March 31, 2025, issued 23,666,666 common shares at $0.015 per share, raising gross proceeds of $355,000. Closing of the private placement is subject to acceptance by the TSX Venture Exchange. No fees were payable on the transaction, and the payments to persons conducting Investor Relations Activities were not more than 10% of the proceeds. The proposed payments from the proceeds included $183,600 to pay outstanding fees to non-arm’s length creditors.

    About International Lithium Corp.

    International Lithium Corp. has exploration activities in Ontario, Canada, with intentions to expand into Southern Africa. It has projects at various stages, ranging from Preliminary Economic Assessment at Raleigh Lake to Pre-Drilling at Wolf Ridge. The primary target metals in Canada are lithium, rubidium and copper. There are three projects (two in Ontario and one in Ireland) in which ILC has sold its share but where we stand to receive future payments from either a resource milestone being achieved or from a Net Smelter Royalty.

    While the world’s politicians are currently divided on the future of the energy market’s historic dependence on oil and gas and on ‘Net Zero’, there seems to be a clear and unstoppable momentum towards electric vehicles, solar power and electric battery storage, all of which contribute to rising demand for lithium. Rubidium is increasingly seen as a valuable critical metal that is strategic for high-precision clocks and for space technology. Copper has many historical uses, but demand is projected to be sharply higher as more data centres are required for AI. We have seen the clear and increasingly urgent wish by the USA, Canada, and other major economies to safeguard their supplies of critical metals and to become more self-sufficient. Our Canadian projects, which contain lithium, rubidium and copper, are strategic in that respect.

    Our key mission for the next decade is to generate revenue for our shareholders from lithium and other battery metals, as well as rare metals, while also contributing to the creation of a greener, cleaner planet and less polluted cities.

    This includes optimizing the value of our existing projects in Canada as well as finding, exploring and developing projects that have the potential to become world-class deposits. We have separately announced that we regard Southern Africa as a key strategic target market for ILC and that we have applied for and hope to receive EPOs in Zimbabwe. We hope to make further announcements on the portfolio developments over the next few weeks and months.

    The Company’s interests in various projects now consist of the following, and in addition, the Company continues to seek other opportunities:

    Name Metal Location Stage Area in 
    Hectares
    Current Ownership Percentage Future Ownership % if options exercised and/or residual interest Operator or 
    JV Partner
    Raleigh 
    Lake
    Lithium
    Rubidium
    Ontario Dec 2023 : PEA for Li completed Apr 2023 Maiden Resource Estimates for Li and Rb 32,900 100% 100% ILC
    Firesteel Copper
    Cobalt
    Ontario Aeromagnetics and Drilling started mid 2024 6,600 90% 90% ILC
    Wolf 
    Ridge
    Lithium Ontario Pre-Drilling 5,700 0% 100% ILC
    Mavis 
    Lake
    Lithium Ontario May 2023
    Maiden Resource Estimate
    2,600 0% 0%
    (carries an extra earn-in payment of AUD$ 0.75 million if resource targets met)
    Critical Resources Ltd 
    Avalonia Lithium Ireland Drilling 29,200 0% 0%
    2.0% Net Smelter Royalty
    GFL Intl Co Ltd (owned by Ganfeng Lithium Group Co.Ltd)
    Forgan/
    Lucky Lakes
    Lithium Ontario Drilling 0% 0%
    1.5% Net Smelter Royalty
    Power Minerals Ltd 

     

    The Company’s primary strategic focus at this point is on the Raleigh Lake Project, comprising lithium and rubidium, and the Firesteel copper project in Canada, as well as obtaining EPOs and mineral claims in Zimbabwe.

    The Raleigh Lake Project now encompasses 32,900 hectares (329 square kilometres) of mineral claims in Ontario and represents ILC’s most significant project in Canada. To date, drilling has occurred on less than 1,000 hectares of our claims. A Preliminary Economic Assessment was published for ILC’s lithium at Raleigh Lake in December 2023, with a detailed economic analysis of ILC’s separate rubidium resource still pending. Raleigh Lake is 100% owned by ILC, free from any encumbrances and royalties. The Raleigh Lake Project boasts excellent access to roads, rail, and utilities.

    A continuing goal has been to remain a well-funded company to turn our aspirations into reality. Following the disposal of the Mariana project in Argentina in 2021, the Mavis Lake project in Canada in 2022, and the Avalonia project in 2024, ILC continues to achieve sufficient inward cash flow to be able to make progress with its exploration projects.

    With the increasing demand for high-tech rechargeable batteries used in electric vehicles, electrical storage, and portable electronics, lithium has been designated ‘the new oil’ and is a key part of a green energy, sustainable economy. By positioning itself with projects that have significant resource potential and solid strategic partners, ILC aims to be one of the preferred lithium and rare metals resource developers for investors and to continue building value for its shareholders for the rest of the 2020s, the decade of battery metals.

    On behalf of the Company,

    John Wisbey
    Chairman and CEO
    www.internationallithium.ca

    For further information concerning this news release, please contact +1 604-449-6520 or info@internationallithium.ca or ILC@yellowjerseypr.com.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Cautionary Statement Regarding Forward-Looking Information

    Except for statements of historical fact, this news release or other releases contain certain ‘forward-looking information’ within the meaning of applicable securities law. Forward-looking information or forward-looking statements in this or other news releases may include: the timing of completion of any offering and the amount to be raised, the time when the Company will receive the remaining consideration payable by Ganfeng for the Avalonia Project, the effect of results of anticipated production rates, the timing and/or anticipated results of drilling on the Raleigh Lake or Firesteel or Wolf Ridge projects, the expectation of resource estimates, preliminary economic assessments, feasibility studies, lithium or rubidium or copper recoveries, modeling of capital and operating costs, results of studies utilizing various technologies at the company’s projects, the Company’s budgeted expenditures, future plans for expansion in Southern Africa and planned exploration work on its projects, increased value of shareholder investments in the Company, the potential from the company’s third party earn-out or royalty arrangements, the future demand for lithium, rubidium and copper, and assumptions about ethical behaviour by our joint venture partners or third party operators of projects or royalty partners. Such forward-looking information is based on assumptions and subject to a variety of risks and uncertainties, including but not limited to those discussed in the sections entitled ‘Risks’ and ‘Forward-Looking Statements’ in the interim and annual Management’s Discussion and Analysis which are available at www.sedar.com. While management believes that the assumptions made are reasonable, there can be no assurance that forward-looking statements will prove to be accurate. Should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking information. Forward-looking information herein, and all subsequent written and oral forward-looking information are based on expectations, estimates and opinions of management on the dates they are made that, while considered reasonable by the Company as of the time of such statements, are subject to significant business, economic, legislative, and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect and are expressly qualified in their entirety by this cautionary statement. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.

    NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE 
    UNITED STATES

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262166

    News Provided by Newsfile via QuoteMedia

    This post appeared first on investingnews.com

    Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; FRANKFURT:1XQ; ‘ BRW ‘ or the ‘ Company ‘) is pleased to announced that it has identified the country’s largest spodumene pegmatite trend. The discovery of multiple new spodumene-bearing pegmatites significantly expands the Ivisaartoq lithium pegmatite field, which was discovered last year on the Nuuk license. This major trend now extends over a strike length of approximately 2 kilometres.

    ‘The discovery of this two-kilometre by three-hundred-metre area of spodumene bearing dykes is a testament to BRW’s systematic and efficient approach,’ said Killian Charles, BRW’s President and CEO. ‘I would like to personally thank the BRW team, Xploration Services Greenland A/S, the Geological Survey of Denmark and Greenland, and the Greenland Mineral Resource Authority for their dedication and support.’

    This exploration success reflects the Company’s consistent, systematic approach to exploration and Brunswick Exploration is currently designing and evaluating the opportune time to begin a comprehensive drill campaign at Ivisaartoq.

    Ivisaartoq Discovery Expansion

    BRW has now identified a minimum of eight pegmatite outcrops that occur within a corridor measuring approximately 2,000 meters long by 300 meters wide, which remains open in all directions. This spodumene corridor is within a larger, highly favorable, geochemically anomalous envelope measuring roughly 3 kilometers by 1.5 kilometers. This envelope contains numerous additional, highly fractionated pegmatites. The company believes that there is potential to host additional spodumene pegmatites at surface and at depth within the aforementioned corridor, the larger geochemically anomalous envelope as well as the entire south Ivisaartoq belt, which measures roughly 20 kilometers in strike (see news release October 30, 2024).

    The surface expression of the spodumene outcrops range in size from roughly 5 to 400 meters in length and 2 to 40 meters in width. The lithium mineralization is predominantly spodumene which varies from sparse to up to 50%, containing white and pale green crystals that range in size from 1 to 40 centimeters. Other minor lithium bearing minerals include holmquistite in the host rocks, elbaite, as well as lepidolite. The Company is already planning an inaugural drill campaign for Ivisaartoq to test the newly discovered outcrops.

    Spodumene mineralization at the newly discovered outcrops was confirmed by both pXRF and LIBS units. Grab and channel samples are being sent for analysis to ALS in Dublin, Ireland, and thin section samples will be prepared and examined for mineralogical understanding. The size, orientation and overall grade of the pegmatite outcrops will be better established as the drill campaign progresses.

    Figure 1: Ivisaartoq Spodumene Trend

    Figure 2: One of the 2025 Spodumene Discovery Outcrops. Helicopters for Scale.

    Figure 3: Spodumene at one of the 2025 Discovery Outcrops

    Qualified Person

    The scientific and technical information related to this press release has been reviewed and approved by Mr. Charles Kodors, Manager, International Projects. He is a Professional Geologist registered in New Brunswick, Newfoundland and Quebec.

    About Brunswick Exploration

    Brunswick Exploration is a Montreal-based mineral exploration company listed on the TSX-V under symbol BRW. The Company is focused on grassroots exploration for lithium in Canada, a critical metal necessary to global decarbonization and energy transition. The company is rapidly advancing its extensive grassroots lithium property portfolio in Canada and Greenland.

    Investor Relations/information

    Mr. Killian Charles, President and CEO ( info@BRWexplo.com )

    Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

    Cautionary Statement on Forward-Looking Information

    This news release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

    Photos accompanying this announcement are available at:
    https://www.globenewswire.com/NewsRoom/AttachmentNg/eadaf730-6329-47ff-ac5a-904ee01d50d6
    https://www.globenewswire.com/NewsRoom/AttachmentNg/3ecca867-4c95-4187-babd-18fca2de3823
    https://www.globenewswire.com/NewsRoom/AttachmentNg/a3fcb401-4c54-49d0-9fc5-cf54dc3769fa

    News Provided by GlobeNewswire via QuoteMedia

    This post appeared first on investingnews.com

    Rio Silver Inc. (‘Rio Silver’ or the ‘Company’) (TSX.V: RYO,OTC:RYOOD) (OTC: RYOOF) announces that, further to the announcements on March 26 and June 25, 2025 (collectively, the ‘Prior Announcements’), it has amended terms of the acquisition (the ‘Transaction’) from Peruvian Metals Corp. (‘Peruvian’) of the Maria Norte Project (the ‘Property’) located in the District of Huachocopla, Huancavelica Peru.

    Subject to applicable regulatory and other approvals including that of the Exchange, the amended terms of the Transaction with Peruvian include: (1) the elimination of the net smelter royalty to Peruvian; (2) the adjusted number of payment securities to be issued to Peruvian, which are now 3,000,000 shares of Rio Silver and 1,000,000 share purchase warrants of Rio Silver (on account of the recent 5:1 consolidation of the shares of Rio Silver, completed on July 3, 2025), with each share purchase warrant exercisable at $0.15 per share for a period of two years from the date of Exchange approval; and (3) payment by Rio Silver to Peruvian in the amount of US$22,500, with all other terms of the Transaction remaining unchanged. For further clarity, the semiannual payments of US$25,000 to Peruvian in the aggregate amount of US$250,000 will remain as ‘Option Payments’, given the elimination of the net smelter royalty.

    About Rio Silver

    Rio Silver is a resource development company that has been selectively identifying and acquiring precious metal assets that are anticipated to produce near-term cashflow to best assist the Company’s exploration / development plans, in a non-dilutive, shareholder-friendly way. We remain ever impressed and optimistic by the resilience and ingenuity of our host country as Peru continues to endorse supportive mining policies and continued growth, as evident by the continuing investment being witnessed throughout Peru.

    ON BEHALF OF THE BOARD OF DIRECTORS OF Rio Silver INC.

    Chris Verrico

    Director, President and Chief Executive Officer

    Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

    For further information,

    Christopher Verrico, President, CEO

    Tel: (604) 762-4448

    Email: chris.verrico@riosilverinc.com

    Website: www.riosilverinc.com

    This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required by applicable laws.

    News Provided by GlobeNewswire via QuoteMedia

    This post appeared first on investingnews.com

    The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

    Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

    The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

    Big pharma ETFs

    Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on August 11, 2025.

    1. iShares US Pharmaceuticals ETF (ARCA:IHE)

    Total assets under management: US$539.44 million

    Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

    Of its holdings, Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are by far the largest portions in its portfolio, coming in at weightings of 25.51 percent and 17.68 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 5.04 percent, Viatris (NASDAQ:VTRS) at 4.94 percent and Merck & Co (NYSE:MRK) at 4.59 percent.

    2. VanEck Pharmaceutical ETF (NASDAQ:PPH)

    Total assets under management: US$494.34 million

    Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

    The ETF has 25 holdings, with the top five being Eli Lilly at a weight of 15.81percent, Johnson & Johnson at 12.08 percent, Novartis (NYSE:NVS) at 7.80 percent, Merck & Co. at 6.33 percent and Novo Nordisk (NYSE:NVO) at 5.94 percent.

    3. Invesco Pharmaceuticals ETF (ARCA:PJP)

    Total assets under management: US$240.1 million

    The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

    This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Johnson & Johnson with a weight of 5.25 percent, Gilead Sciences (NASDAQ:GILD) at 5.08 percent, AbbVie (NYSE:ABBV) at 4.95 percent, and both Pfizer (NYSE:PFE) and Merck & Co. at 4.83 percent each.

    4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

    Total assets under management: US$150.91 million

    The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

    This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Elanco Animal Health (NYSE:ELAN) with a weight of 4.21 percent, Tarsus Pharmaceuticals (NASDAQ:TARS) with a weight of 4.18 percent, Johnson & Johnson at 4.02 percent, Royalty Pharma at 3.98 percent and Viatris at 3.89 percent.

    5. KraneShares MSCI All China Health Care Index ETF

    Total assets under management: US$111.67 million

    The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

    The ETF tracks 46 holdings, and its top five are BeOne Medicines at 8.26 percent, Jiangsu Hengrui Medicine (SHA:600276) at 8.24 percent, WuXi Biologics (HKEX:2269) at 6.71 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 5.95 percent and CSPC Pharmaceutical Group (HKEX:1093) at 5.39 percent.

    Securities Disclosure: I, Meagen Seatter, hold no investment interest in any of the companies mentioned in this article.

    This post appeared first on investingnews.com

    Keith Weiner, founder and CEO of Monetary Metals, discusses gold and silver’s performance so far this year and shares his outlook for the rest of 2025.

    He also explains what makes today’s gold bull market different than those seen in prior years.

    Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.

    After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,530.69 as of August 5, 2025, further growth could be in store in the future.

    According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.04 trillion.

    Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.

    The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.

    Data was gathered on August 5, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.

    1. Tiziana Life Sciences (NASDAQ:TLSA)

    Year-to-date gain: 227.8 percent
    Market cap: US$256.36 million
    Share price: US$2.26

    Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous delivery. Tiziana’s lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody.

    Tiziana Life Sciences shares hit US$1.69 on March 7 after the company filed its investigational new drug application to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association. However, by early April that value had fallen back to US$0.78 per share.

    A series of positive news flow later in the spring helped to give Tiziana shares another boost. In April, John Hopkins University and the University of Massachusetts commenced dosing of the biotech company’s intranasal foralumab in Phase 2 trials for patients with non-active secondary progressive multiple sclerosis. On May 7, the company shared positive results from the use of its lead candidate in improving the quality of life for patients with that form of multiple sclerosis.

    Tiziana is also studying the use of intranasal foralumab for treating moderate Alzheimer’s disease. On May 9, it announced that PET scans of a patient with moderate Alzheimer’s showed a significant reduction in microglia activation associated with neuroinflammation after three months of treatment.

    Shares of Tiziana reached US$1.62 on May 13.

    On July 21, the company announced an ‘unexpected discovery’ in its findings of an immunologic analysis of the patient with Alzheimer’s disease.

    ‘In an unexpected discovery, the analysis revealed an increase in phagocytosis markers in classical monocytes, suggesting that nasal foralumab may enhance their ability to clear amyloid plaques,’ the press release states. ‘This unexpected effect may open new avenues for treating Alzheimer’s Disease by targeting both inflammation and amyloid accumulation.’

    Tiziana’s share price climbed through the remainder of the month, hitting a year-to-date high of US$2.50 on July 31.

    2. Palvella Therapeutics (NASDAQ:PVLA)

    Year-to-date gain: 224.98 percent
    Market cap: US$416.08 million
    Share price: US$37.64

    Palvella Therapeutics is a clinical-stage biopharma developing treatments targeting rare genetic skin diseases for which there are no FDA-approved therapies. The company’s product pipeline centers on its patented QTORIN platform, which has an initial focus on rare genetic skin diseases.

    Its lead product candidate, QTORIN rapamycin, is currently in a Phase 2 clinical trial in cutaneous venous malformations, and a Phase 3 clinical trial in microcystic lymphatic malformations (LM). QTORIN rapamycin has been granted breakthrough therapy designation, orphan drug designation and fast track designation from the FDA for the treatment of microcystic LMs.

    After starting the year at US$12.00, shares of Palvella had surged to US$20.99 by February 18. About a week earlier, the company had shared plans to expand the Phase 3 trial to include pediatric patients from three to five years of age. That momentum in Palvella’s share price continued to rally to US$29 per share on March 13.

    June produced a number of significant milestones for Palvella. On June 9, the company received initial proceedings from a grant issued by the FDA Office of Orphan Products Development for its Phase 3 trial, and on June 23, it completed enrollment for the trial with 51 subjects, 25 percent over its target. The company closed out the month with news it was added to the broad-market Russell 3000 Index and the Russell 2000 Index.

    The company said it remains on track to deliver top-line Phase 3 data in Q1 2026 to support its planned new drug application submission later that year.

    While the company didn’t release news in July, Palvella Therapeutics’ share price climbed significantly through the month to hit a year-to-date high of US$39.87 on July 28.

    3. OKYO Pharma (NASDAQ:OKYO)

    Year-to-date gain: 163.03 percent
    Market cap: US$117.35 million
    Share price: US$3.13

    OKYO Pharma is a clinical-stage biopharma developing therapies for the treatment of neuropathic corneal pain and dry eye disease. Its lead candidate is urcosimod, a non-steroidal anti-inflammatory and non-opioid analgesic.

    So far in 2025, the company has achieved multiple milestones related to its Phase 2 trial of urcosimod for treatment of neuropathic corneal pain.

    On April 30, OKYO announced plans to end the trial early to analyze the data from the patients who had completed the trial, with the goal of accelerating its clinical development and expanding the program. Supporting the decision was the fact that urcosimod had previously demonstrated safety in OKYO’s completed Phase 2 trial of the candidate to treat patients with dry eye disease.

    The next day, news broke that the FDA granted urcosimod fast track designation for the treatment of neuropathic corneal pain. OKYO’s stock price reached US$1.57 on May 1.

    On July 17, OKYO posted strong top-line data from its Phase 2 clinical trial, and stated it is planning a meeting with the FDA to discuss next steps for its lead drug candidate. The following day, OKYO received US$1.9 million in non-dilutive funding to support its clinical development of urcosimod.

    Shares of OKYO hit a year-to-date high of US$3.17 on August 5.

    4. IO Biotech (NASDAQ:IOBT)

    Year-to-date gain: 129.47 percent
    Market cap: US$144.28 million
    Share price: US$2.16

    IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating therapeutic cancer vaccines based on its T-win technology platform, designed to activate T cells to target both tumor cells and the immune-suppressive cells. The company’s lead cancer vaccine candidate IO102-IO103, which has the brand name Cylembio, is currently in clinical trials.

    The FDA granted breakthrough therapy designation to IO102-IO103 when used in combination with Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA for the treatment of advanced melanoma based on positive Phase 1/2 first line metastatic melanoma data.

    At the start of the year, IO Biotech completed enrollment in its Phase 2 trial of IO102-IO103 with KEYTRUDA as a treatment given before and after surgery for resectable melanoma or head and neck cancer.

    On February 4, the company published results from a preclinical study of its second immune-modulatory therapeutic cancer vaccine candidate, IO112, targeting arginase 1, which plays a key role in immune suppression.

    In mid-March, IO Biotech was named to Fast Company’s list of the World’s Most Innovative Companies of 2025. The following month, the company presented new preclinical data for its lead candidate IO102-IO103 as well as IO170, which targets Transforming Growth Factor beta.

    In its Q1 2025 financial results and business highlights released on May 14, IO Biotech shared that a readout of primary endpoint data from its pivotal Phase 3 trial of its lead investigational therapeutic cancer vaccine in patients with advanced melanoma is expected in the third quarter of 2025.

    Shares of IO Biotech reached a year-to-date high of US$2.40 on July 28.

    5. Spero Therapeutics (NASDAQ:SPRO)

    Year-to-date gain: 110.95 percent
    Market cap: US$124.12 million
    Share price: US$2.22

    Spero Therapeutics is developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need. The company’s lead drug candidate is tebipenem pivoxil hydrobromide (HBr), a late-stage development asset developed in collaboration with pharma giant GSK (NYSE:GSK) to treat complicated urinary tract infections (cUTIs), including pyelonephritis.

    Spero has an exclusive license agreement with GSK for the development and commercialization of the drug candidate in all ex-Asia markets. The FDA has granted tebipenem HBr qualified infectious disease product and fast track designations.

    Shares in Spero traded below US$1.00 for much of the first half of 2025. However, the stock’s value surged 245 percent on May 28 to reach US$2.35 per share after Spero reported that its Phase 3 trial evaluating tebipenem HBr for treating cUTIs met its primary endpoint and stopped early for efficacy. GSK plans to include the findings in a filing to the FDA during H2.

    Spero shares reached a year-to-date high of US$3.04 on July 9.

    Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    (TheNewswire)

    TORONTO, ON, August 13, 2025 TheNewswire – Silver Crown Royalties Inc. ( Cboe: SCRI,OTC:SLCRF; OTCQX: SLCRF; FRA: QS0) ( ‘Silver Crown’ or the ‘Company’ ) is pleased to announce that, further to its press release dated August 7, 2025, it has closed the acquisition of a royalty on 90% of the cash equivalent of silver produced each quarter from the past producing Scotia Mine (the ‘Silver Royalty’ ) with EDM Resources Inc. ( TSX-V: EDM; FSE: P3Z) ( ‘EDM’ ). The Silver Royalty provides for minimum of the cash equivalent of 7,000 ounces per year for 10 years starting at commercial production on the Scotia Mine. SCRi paid $250,000 in cash at closing and issued 60,000 units (‘ Units ‘) to EDM per Unit at a deemed value of C$10.00, with each Unit consisting of a common share in the capital of SCRi (‘ Common Share ‘) and one warrant exercisable into an additional Common Share at a price of C$13.00 for a period of 36 months following the date hereof. SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty.

    ABOUT EDM RESOURCES INC.

    EDM Resources Inc. (‘EDM’) ( TSX-V: EDM; FSE: P3Z) is a Canadian exploration and mining company that has full ownership of the Scotia Mine and related facilities near Halifax, Nova Scotia. Through its wholly owned subsidiary, EDM also holds several prospective exploration licenses near its Scotia Mine and in the surrounding regions of Nova Scotia .

    ABOUT Silver Crown Royalties INC.

    Founded by seasoned industry professionals, Silver Crown Royalties ( Cboe: SCRI | OTCQX: SLCRF | FRA: QS0) is a publicly traded silver royalty company dedicated to generating free cash flow. Silver Crown (SCRi) currently holds five silver royalties. Its business model offers investors exposure to precious metals, providing a natural hedge against currency devaluation while mitigating the adverse effects of production-related cost inflation. SCRi strives to minimize the economic burden on mining projects while simultaneously maximizing shareholder returns. For further information, please contact:

    Silver Crown Royalties Inc.

    Peter Bures, Chairman and CEO

    Telephone: (416) 481-1744

    Email: pbures@silvercrownroyalties.com

    FORWARD-LOOKING STATEMENTS

    This release contains certain ‘forward looking statements’ and certain ‘forward-looking information’ as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as ‘may’, ‘will’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘believe’, ‘continue’, ‘plans’ or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, SCRi must pay EDM an additional C$250,000 cash payment following the date hereof as deferred consideration for the Silver Royalty . Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the impact of general business and economic conditions; the absence of control over mining operations from which SCRi will purchase gold and other metals or from which it will receive royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans continue to be refined; accidents, equipment breakdowns, title matters, labor disputes or other unanticipated difficulties or interruptions in operations; SCRi’s ability to enter into definitive agreements and close proposed royalty transactions; the inherent uncertainties related to the valuations ascribed by SCRi to its royalty interests; problems inherent to the marketability of gold and other metals; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; industry conditions, including fluctuations in the price of the primary commodities mined at such operations, fluctuations in foreign exchange rates and fluctuations in interest rates; government entities interpreting existing tax legislation or enacting new tax legislation in a way which adversely affects SCRi; stock market volatility; regulatory restrictions; liability, competition, the potential impact of epidemics, pandemics or other public health crises on SCRi’s business, operations and financial condition, loss of key employees. SCRi has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SCRi undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available.

    This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities of the Company in Canada, the United States or any other jurisdiction. Any such offer to sell or solicitation of an offer to buy the securities described herein will be made only pursuant to subscription documentation between the Company and prospective purchasers. Any such offering will be made in reliance upon exemptions from the prospectus and registration requirements under applicable securities laws, pursuant to a subscription agreement to be entered into by the Company and prospective investors. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.

    CBOE CANADA DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

    Copyright (c) 2025 TheNewswire – All rights reserved.

    News Provided by TheNewsWire via QuoteMedia

    This post appeared first on investingnews.com